search
Back to results

TECR & ECM Placement for Esophageal High Grade Dysplasia

Primary Purpose

Barrett Esophagus, Esophagus, High Grade Dysplasia

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex))
Sponsored by
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Barrett Esophagus

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Be at least 18 years of age and no more than 80 years of age.
  2. Have an established diagnosis of HGD

    a. Specific diagnosis and grading will be determined by pathology review of biopsy tissue collected during baseline EGD as part of a patient's standard of care.

  3. Have no evidence of lymphovascular invasion.
  4. Have no lymph node or other metastatic involvement based on EUS and FDG-PET/CT.
  5. Diameter of affected tissue must warrant circumferential excision a. Subjects must have biopsy confirmed HGD in three of four esophageal quadrants at two levels spaced two centimeters apart (minimum of 6/8 biopsies indicating HGD). If two biopsies are normal (contain no HGD) they must be located on separate levels in two different quadrants.

5. Must be an appropriate or reasonable surgical candidate. 6. Have demonstrated an understanding and signed an approved informed consent form for participation in this study.

Exclusion Criteria:

  1. Have lesions into or deeper than mucosal layer (superficial (T1a) Esophageal adenocarcinoma).

    a. Those requiring endoscopic submucosal dissection (ESD) are not eligible for this study

  2. Have presence of lymphovascular invasion.
  3. Require resection length longer than 10 cm.
  4. Have any lymph node or other metastatic involvement based on EUS and FDG-PET/CT.
  5. Have history of any kind of previous esophageal surgery (i.e. anti-reflux surgery).
  6. Are pregnant or planning to become pregnant.
  7. Have coagulation disorders.
  8. Have a known hypersensitivity to porcine-based materials.
  9. Have an uncontrolled comorbid medical condition that would adversely affect participation in the trial.
  10. Has a clinically significant psychological illness that in the physician's opinion would prohibit the subject's ability to meet the protocol requirements.
  11. Are unable or unwilling to provide informed consent and/or fulfill the protocol follow-up requirements.

    -

Sites / Locations

  • West Penn Allegheny Health System

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

TECR & ECM

Arm Description

Subjects undergoing TECR with ECM placement Intervention is Trans-oral Endoscopic circumferential resection (TECR) with placement of extra-cellular matrix (ECM)

Outcomes

Primary Outcome Measures

Efficacy: Stricture Formation
To evaluate incidence of stricture formation requiring dilation (≥30% luminal diameter reduction with dysphagia) following TECR with ECM placement. Evidence of stricture formation will be confirmed endoscopically at 2 weeks, and endoscopically and through barium swallow at Month 1, Month 3, Month 6, Month 9, and Month 12 post procedure, and the proportion of subjects with and without stricture formation at the trial endpoints will be compared to historical data.
Efficacy: Recurrent Disease
To evaluate incidence of recurrence of BE with HGD through 12 months following TECR with ECM placement. Incidence of disease recurrence will be confirmed endoscopically with pathology confirmed biopsies at 2 weeks, Month 1, Month 3, Month 6, Month 9, and Month 12 post procedure, and the proportion of subjects with and without disease recurrence at the trial endpoints will be compared to historical data.
Safety: Acute (Serious System and Procedure Related Adverse Events)
To demonstrate the acute safety of TECR with ECM placement for treatment of BE with HGD by evaluating all serious system and procedure related adverse events occurring in the first 2 weeks post procedure.
Safety: Long-term (Study Related Adverse Events)
To demonstrate the long-term safety of TECR with ECM placement for treatment of BE with HGD by evaluating all study related adverse events occurring more than 2 weeks post procedure through 12 months post procedure.

Secondary Outcome Measures

Stent Migration
To record the incidence of stent migration at 2 weeks post procedure. Stent migration will be determined endoscopically, and defined as any movement from initial deployment location greater than 1cm.
Stent Integrity (e.g. Stent Fracture)
To record incidences of poor stent integrity during removal (e.g. stent fracture).
Additional Interventions (Number of Subsequent Follow up Treatment Interventions)
To record the number of subsequent follow up treatment interventions (aside from study-related follow up time points) required post-procedure through 12 months.

Full Information

First Posted
March 19, 2015
Last Updated
February 22, 2019
Sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Collaborators
Integra LifeSciences Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT02396745
Brief Title
TECR & ECM Placement for Esophageal High Grade Dysplasia
Official Title
A Prospective Feasibility Study to Evaluate the Safety and Efficacy of Transoral Endoscopic Circumferential Esophageal Resection With Extracellular Matrix (ECM) Placement to Treat Barrett's Esophagus With High-grade Dysplasia (HGD)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Terminated
Why Stopped
Serious Adverse Event of Patient who completed study and follow-up.
Study Start Date
January 25, 2016 (Actual)
Primary Completion Date
March 22, 2018 (Actual)
Study Completion Date
March 22, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Collaborators
Integra LifeSciences Corporation

4. Oversight

Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will test the safety and effectiveness of esophageal transoral endoscopic circumferential resection (TECR) using an extracellular matrix (ECM) placement to treat Barrett's esophagus in patients with high-grade dysplasia (HGD). Endoscopic circumferential resection using ECM placement has been introduced as a less invasive, externally incision-less approach to treat patients with esophageal high grade dysplasia; a pre-cancerous condition. In this procedure, the entire length of diseased (abnormal) mucosa (esophagus lining) will be removed using an endoscope that will be inserted through the mouth. The ECM will be placed over the area that is being removed with a temporary, expandable stent to prevent narrowing of the esophagus. The stent is being used to hold the ECM in place as the body begins the healing process. This stent will be removed 14 days (±4 days) after this procedure. Follow-up esophagogastroduodenoscopies (EGD), barium swallow x-ray tests, and questionnaires will take place for 12 months following the procedure. The result of this study may help doctors determine if this procedure would be a more effective treatment option for HGD in the future.
Detailed Description
This is a single-center, prospective, single arm study involving 10 patients with an established diagnosis of Barrett's Esophagus (BE) with High Grade Dysplasia (HGD). Potential subjects will be prescreened to assess eligibility and must meet inclusion criteria. In order to make this initial qualification, pathology results of biopsies and EMR collected during initial EGD will be made available to the Investigator prior to patient consent. Following informed consent and as part of routine care, all potential participants will undergo endoscopic ultrasound (EUS) and a PET/CT scan to confirm that there is no lymph node involvement or other metastatic lesions prior to the procedure. Clinical data will be collected at baseline to assess the subjects' medical status including: demographics, medical history, physical examination, vital signs, and blood testing. Cardiac and pulmonary clearance will be obtained if needed based on medical history and will include a chest x-ray, ECG, and pulmonary function test. In addition, the subjects will complete three questionnaires prior to the procedure: dysphagia severity questionnaire, SF-36, and GERD-HRQL. At the time of the procedure, participants will undergo TECR with ECM placement using a fully covered self-expanding metal stent to temporarily hold the ECM in place. Prior to hospital discharge, a barium swallow test (BaSW) will be performed at Day 1 following the study procedure to evaluate the passage of contrast through the GEJ. If the BaSW results in suspicious findings of esophageal perforation or mucosal necrosis, an upper endoscopy will be performed for further evaluation. The first primary safety endpoint for this study will be assessed following the procedure and BaSW and before discharge from the hospital. At this time point any adverse events will be assessed and recorded. All subjects will undergo the same follow-up procedures, including questionnaires and post-procedure EGDs performed at Week 2, Month 1, Month 3, Month 6, Month 9 and Month 12 to visually assess tissue healing, recurrent disease, and if stricture formation is present. Biopsies will be taken during follow-up EGDs so that pathology can rule out recurrence of BE and HGD. Subjects will have a barium swallow x-ray at Month 1, Month 3, Month 6, Month 9, and Month 12 to evaluate the potential presence of stricture formation. During Week 2 EGD, the stent will be removed during the upper endoscopy. If at any time point a subject has dysphagia with stricture formation (30% reduction in esophageal luminal diameter), routine dilation using a balloon catheter will be performed during the EGD. Validated questionnaires including dysphagia severity questionnaire, SF-36 and GERD-HRQL will be administered to objectively assess the severity of symptoms and quality of life based upon self-reported data. Additionally, adverse events will be assessed and recorded at all follow-up time points. After completion of the Month 12 visit, subjects will be followed on a routine care basis at the Esophageal & Lung Institute.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Barrett Esophagus, Esophagus, High Grade Dysplasia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
1 (Actual)

8. Arms, Groups, and Interventions

Arm Title
TECR & ECM
Arm Type
Experimental
Arm Description
Subjects undergoing TECR with ECM placement Intervention is Trans-oral Endoscopic circumferential resection (TECR) with placement of extra-cellular matrix (ECM)
Intervention Type
Device
Intervention Name(s)
Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex))
Other Intervention Name(s)
ACell, Inc. MatriStem® Surgical Matrix PSMX, Boston Scientific, WallFlex™ Fully Covered Esophageal Stent
Intervention Description
TECR will be performed to resect the entire length and area of BE lesion. ECM PLACEMENT: Following resection, the exposed area will be covered with a 6 ply sheet of ACell MatriStem® Surgical Matrix PSMX ECM (ACell Inc., Columbia, MA). The ECM will be placed and held in position for 14 days (±4 days) using a Boston Scientific WallFlex™ Fully Covered Esophageal Stent (Boston Scientific, Boston, MA).
Primary Outcome Measure Information:
Title
Efficacy: Stricture Formation
Description
To evaluate incidence of stricture formation requiring dilation (≥30% luminal diameter reduction with dysphagia) following TECR with ECM placement. Evidence of stricture formation will be confirmed endoscopically at 2 weeks, and endoscopically and through barium swallow at Month 1, Month 3, Month 6, Month 9, and Month 12 post procedure, and the proportion of subjects with and without stricture formation at the trial endpoints will be compared to historical data.
Time Frame
12 months following procedure
Title
Efficacy: Recurrent Disease
Description
To evaluate incidence of recurrence of BE with HGD through 12 months following TECR with ECM placement. Incidence of disease recurrence will be confirmed endoscopically with pathology confirmed biopsies at 2 weeks, Month 1, Month 3, Month 6, Month 9, and Month 12 post procedure, and the proportion of subjects with and without disease recurrence at the trial endpoints will be compared to historical data.
Time Frame
12 months following procedure
Title
Safety: Acute (Serious System and Procedure Related Adverse Events)
Description
To demonstrate the acute safety of TECR with ECM placement for treatment of BE with HGD by evaluating all serious system and procedure related adverse events occurring in the first 2 weeks post procedure.
Time Frame
Two weeks following procedure
Title
Safety: Long-term (Study Related Adverse Events)
Description
To demonstrate the long-term safety of TECR with ECM placement for treatment of BE with HGD by evaluating all study related adverse events occurring more than 2 weeks post procedure through 12 months post procedure.
Time Frame
Two weeks through 12 months post procedure
Secondary Outcome Measure Information:
Title
Stent Migration
Description
To record the incidence of stent migration at 2 weeks post procedure. Stent migration will be determined endoscopically, and defined as any movement from initial deployment location greater than 1cm.
Time Frame
2 weeks
Title
Stent Integrity (e.g. Stent Fracture)
Description
To record incidences of poor stent integrity during removal (e.g. stent fracture).
Time Frame
2 weeks
Title
Additional Interventions (Number of Subsequent Follow up Treatment Interventions)
Description
To record the number of subsequent follow up treatment interventions (aside from study-related follow up time points) required post-procedure through 12 months.
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Be at least 18 years of age and no more than 80 years of age. Have an established diagnosis of HGD a. Specific diagnosis and grading will be determined by pathology review of biopsy tissue collected during baseline EGD as part of a patient's standard of care. Have no evidence of lymphovascular invasion. Have no lymph node or other metastatic involvement based on EUS and FDG-PET/CT. Diameter of affected tissue must warrant circumferential excision a. Subjects must have biopsy confirmed HGD in three of four esophageal quadrants at two levels spaced two centimeters apart (minimum of 6/8 biopsies indicating HGD). If two biopsies are normal (contain no HGD) they must be located on separate levels in two different quadrants. 5. Must be an appropriate or reasonable surgical candidate. 6. Have demonstrated an understanding and signed an approved informed consent form for participation in this study. Exclusion Criteria: Have lesions into or deeper than mucosal layer (superficial (T1a) Esophageal adenocarcinoma). a. Those requiring endoscopic submucosal dissection (ESD) are not eligible for this study Have presence of lymphovascular invasion. Require resection length longer than 10 cm. Have any lymph node or other metastatic involvement based on EUS and FDG-PET/CT. Have history of any kind of previous esophageal surgery (i.e. anti-reflux surgery). Are pregnant or planning to become pregnant. Have coagulation disorders. Have a known hypersensitivity to porcine-based materials. Have an uncontrolled comorbid medical condition that would adversely affect participation in the trial. Has a clinically significant psychological illness that in the physician's opinion would prohibit the subject's ability to meet the protocol requirements. Are unable or unwilling to provide informed consent and/or fulfill the protocol follow-up requirements. -
Facility Information:
Facility Name
West Penn Allegheny Health System
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15224
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
9527214
Citation
Rice TW, Zuccaro G Jr, Adelstein DJ, Rybicki LA, Blackstone EH, Goldblum JR. Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg. 1998 Mar;65(3):787-92. doi: 10.1016/s0003-4975(97)01387-8.
Results Reference
background
PubMed Identifier
19826883
Citation
Witteman BP, Foxwell TJ, Monsheimer S, Gelrud A, Eid GM, Nieponice A, O'Rourke RW, Hoppo T, Bouvy ND, Badylak SF, Jobe BA. Transoral endoscopic inner layer esophagectomy: management of high-grade dysplasia and superficial cancer with organ preservation. J Gastrointest Surg. 2009 Dec;13(12):2104-12. doi: 10.1007/s11605-009-1053-x. Epub 2009 Oct 14.
Results Reference
background
PubMed Identifier
15922361
Citation
Badylak SF, Vorp DA, Spievack AR, Simmons-Byrd A, Hanke J, Freytes DO, Thapa A, Gilbert TW, Nieponice A. Esophageal reconstruction with ECM and muscle tissue in a dog model. J Surg Res. 2005 Sep;128(1):87-97. doi: 10.1016/j.jss.2005.03.002.
Results Reference
background
PubMed Identifier
17126109
Citation
Nieponice A, Gilbert TW, Badylak SF. Reinforcement of esophageal anastomoses with an extracellular matrix scaffold in a canine model. Ann Thorac Surg. 2006 Dec;82(6):2050-8. doi: 10.1016/j.athoracsur.2006.06.036.
Results Reference
background
PubMed Identifier
18657808
Citation
Nieponice A, McGrath K, Qureshi I, Beckman EJ, Luketich JD, Gilbert TW, Badylak SF. An extracellular matrix scaffold for esophageal stricture prevention after circumferential EMR. Gastrointest Endosc. 2009 Feb;69(2):289-96. doi: 10.1016/j.gie.2008.04.022. Epub 2008 Jul 26.
Results Reference
background
PubMed Identifier
21306292
Citation
Badylak SF, Hoppo T, Nieponice A, Gilbert TW, Davison JM, Jobe BA. Esophageal preservation in five male patients after endoscopic inner-layer circumferential resection in the setting of superficial cancer: a regenerative medicine approach with a biologic scaffold. Tissue Eng Part A. 2011 Jun;17(11-12):1643-50. doi: 10.1089/ten.TEA.2010.0739. Epub 2011 Mar 28.
Results Reference
background
PubMed Identifier
22736346
Citation
Hoppo T, Badylak SF, Jobe BA. A novel esophageal-preserving approach to treat high-grade dysplasia and superficial adenocarcinoma in the presence of chronic gastroesophageal reflux disease. World J Surg. 2012 Oct;36(10):2390-3. doi: 10.1007/s00268-012-1698-6.
Results Reference
background
PubMed Identifier
21549373
Citation
Buscaglia JM, Ho S, Sethi A, Dimaio CJ, Nagula S, Stavropoulos SN, Gonda TA, Poneros JM, Stevens PD. Fully covered self-expandable metal stents for benign esophageal disease: a multicenter retrospective case series of 31 patients. Gastrointest Endosc. 2011 Jul;74(1):207-11. doi: 10.1016/j.gie.2011.02.024. Epub 2011 May 6. No abstract available.
Results Reference
background
PubMed Identifier
21826422
Citation
Liu J, Hu Y, Cui C, Li Y, Lin X, Fu J. Removable, fully covered, self-expandable metal stents for the treatment of refractory benign esophagogastric anastomotic strictures. Dysphagia. 2012 Jun;27(2):260-4. doi: 10.1007/s00455-011-9361-1. Epub 2011 Aug 9.
Results Reference
background
PubMed Identifier
20883848
Citation
Bakken JC, Wong Kee Song LM, de Groen PC, Baron TH. Use of a fully covered self-expandable metal stent for the treatment of benign esophageal diseases. Gastrointest Endosc. 2010 Oct;72(4):712-20. doi: 10.1016/j.gie.2010.06.028.
Results Reference
background
PubMed Identifier
19491851
Citation
Eloubeidi MA, Lopes TL. Novel removable internally fully covered self-expanding metal esophageal stent: feasibility, technique of removal, and tissue response in humans. Am J Gastroenterol. 2009 Jun;104(6):1374-81. doi: 10.1038/ajg.2009.133. Epub 2009 Apr 28.
Results Reference
background
PubMed Identifier
15505317
Citation
Yoon CJ, Shin JH, Song HY, Lim JO, Yoon HK, Sung KB. Removal of retrievable esophageal and gastrointestinal stents: experience in 113 patients. AJR Am J Roentgenol. 2004 Nov;183(5):1437-44. doi: 10.2214/ajr.183.5.1831437.
Results Reference
background
PubMed Identifier
16860080
Citation
Baron TH, Burgart LJ, Pochron NL. An internally covered (lined) self-expanding metal esophageal stent: tissue response in a porcine model. Gastrointest Endosc. 2006 Aug;64(2):263-7. doi: 10.1016/j.gie.2006.03.936.
Results Reference
background
PubMed Identifier
20029413
Citation
Sharma P, Kozarek R; Practice Parameters Committee of American College of Gastroenterology. Role of esophageal stents in benign and malignant diseases. Am J Gastroenterol. 2010 Feb;105(2):258-73; quiz 274. doi: 10.1038/ajg.2009.684. Epub 2009 Dec 22.
Results Reference
background
PubMed Identifier
20940709
Citation
Hirdes MM, Siersema PD, Houben MH, Weusten BL, Vleggaar FP. Stent-in-stent technique for removal of embedded esophageal self-expanding metal stents. Am J Gastroenterol. 2011 Feb;106(2):286-93. doi: 10.1038/ajg.2010.394. Epub 2010 Oct 12.
Results Reference
background
PubMed Identifier
20485137
Citation
van Heijl M, Gooszen JA, Fockens P, Busch OR, van Lanschot JJ, van Berge Henegouwen MI. Risk factors for development of benign cervical strictures after esophagectomy. Ann Surg. 2010 Jun;251(6):1064-9. doi: 10.1097/SLA.0b013e3181deb4b7.
Results Reference
background

Learn more about this trial

TECR & ECM Placement for Esophageal High Grade Dysplasia

We'll reach out to this number within 24 hrs